|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
20
|
|
pubmed:dateCreated |
2011-5-19
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
There are few comparisons of antibody induction therapy allowing early glucocorticoid withdrawal in renal-transplant recipients. The purpose of the present study was to compare induction therapy involving alemtuzumab with the most commonly used induction regimens in patient populations at either high immunologic risk or low immunologic risk.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Antilymphocyte Serum,
http://linkedlifedata.com/resource/pubmed/chemical/Glucocorticoids,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Fusion Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/alemtuzumab,
http://linkedlifedata.com/resource/pubmed/chemical/basiliximab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1533-4406
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
19
|
|
pubmed:volume |
364
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1909-19
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:21591943-Acute Disease,
pubmed-meshheading:21591943-Adolescent,
pubmed-meshheading:21591943-Adult,
pubmed-meshheading:21591943-Aged,
pubmed-meshheading:21591943-Animals,
pubmed-meshheading:21591943-Antibodies, Monoclonal,
pubmed-meshheading:21591943-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:21591943-Antibodies, Neoplasm,
pubmed-meshheading:21591943-Antilymphocyte Serum,
pubmed-meshheading:21591943-Biopsy,
pubmed-meshheading:21591943-Drug Therapy, Combination,
pubmed-meshheading:21591943-Female,
pubmed-meshheading:21591943-Glucocorticoids,
pubmed-meshheading:21591943-Graft Rejection,
pubmed-meshheading:21591943-Humans,
pubmed-meshheading:21591943-Immunosuppressive Agents,
pubmed-meshheading:21591943-Kaplan-Meier Estimate,
pubmed-meshheading:21591943-Kidney,
pubmed-meshheading:21591943-Kidney Transplantation,
pubmed-meshheading:21591943-Lymphocyte Count,
pubmed-meshheading:21591943-Male,
pubmed-meshheading:21591943-Middle Aged,
pubmed-meshheading:21591943-Prospective Studies,
pubmed-meshheading:21591943-Rabbits,
pubmed-meshheading:21591943-Recombinant Fusion Proteins,
pubmed-meshheading:21591943-Young Adult
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Alemtuzumab induction in renal transplantation.
|
|
pubmed:affiliation |
University of Alabama at Birmingham, Birmingham, USA. michael.hanaway@ccc.uab.edu
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
